PUBLISHER: The Business Research Company | PRODUCT CODE: 1751009
PUBLISHER: The Business Research Company | PRODUCT CODE: 1751009
Gastrointestinal (GI) stool testing involves analyzing stool samples to evaluate gastrointestinal health, detect infections, digestive disorders, and inflammatory conditions. It aids in identifying microbial imbalances, digestive enzyme deficiencies, and markers of gut inflammation, making it a non-invasive diagnostic tool for early disease detection and personalized treatment planning.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main types of GI stool tests include immunoassay tests, molecular diagnostic tests, chromatography-based tests, microbiological culture tests, and enzyme-linked immunosorbent assay (ELISA). An immunoassay test is a diagnostic method that uses antibodies to identify specific antigens or proteins in stool samples. It can use both fecal and serum samples and requires various types of equipment, including automated analyzers, benchtop instruments, and portable devices. Immunoassay tests are used for diagnosing gastrointestinal disorders, screening for colorectal cancer, monitoring inflammatory bowel disease (IBD), detecting gastrointestinal infections, and evaluating digestive health. These tests are employed by hospitals, diagnostic centers and laboratories, academic institutions, research organizations, home care settings, and others.
The GI stool testing market research report is one of a series of new reports from The Business Research Company that provides GI stool testing market statistics, including GI stool testing industry global market size, regional shares, competitors with a GI stool testing market share, detailed GI stool testing market segments, market trends and opportunities, and any further data you may need to thrive in the GI stool testing industry. This GI stool testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The GI stool testing market size has grown strongly in recent years. It will grow from$1.32 billion in 2024 to $1.41 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth during the historic period can be attributed to the rising prevalence of gastrointestinal diseases, increasing awareness of gut health, greater adoption of automated systems, growing disposable income, and the expanding geriatric population.
The GI stool testing market size is expected to see strong growth in the next few years. It will grow to$1.87 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to the increasing demand for efficient diagnostic instruments, the rising prevalence of colorectal cancer, higher healthcare expenditure, growing consumption of fast food, and an increasing focus on personalized medicine. Major trends in the forecast period include innovations in diagnostic technologies, advancements in molecular diagnostics, progress in biologics, the rise of personalized medicine, and strategic collaborations.
The growing prevalence of gastrointestinal disorders is anticipated to drive the growth of the GI stool testing market in the near future. Gastrointestinal disorders encompass conditions that affect the digestive system, including the stomach, intestines, and related organs, leading to symptoms such as nausea, diarrhea, constipation, and abdominal pain. The rise in such disorders is mainly attributed to poor dietary habits, including increased consumption of processed foods, high sugar intake, and low-fiber diets. These factors disrupt gut microbiota, impair digestive health, and contribute to conditions such as acid reflux, irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD). GI stool testing is essential for diagnosing these conditions as it helps identify infections, inflammation, or digestive imbalances by detecting pathogens (bacteria, viruses, parasites), markers of gut inflammation, and digestive enzyme deficiencies. This enables accurate diagnosis and targeted treatment. For example, in September 2024, the Centers for Disease Control and Prevention (CDC) reported 1,676 norovirus outbreaks in NoroSTAT-participating states between 2024 and 2025, marking a significant increase from the 729 outbreaks recorded during the same period the previous year. Thus, the rising prevalence of gastrointestinal disorders is fueling the growth of the GI stool testing market.
The expansion of healthcare infrastructure is expected to further propel the growth of the GI stool testing market. Healthcare infrastructure includes the physical, technological, and organizational systems needed to deliver medical services, such as hospitals, clinics, equipment, and digital health systems. The expansion of this infrastructure is driven by increasing populations and aging demographics, as longer life expectancies and a higher prevalence of diseases necessitate more medical facilities to ensure adequate healthcare access and improved patient outcomes. Enhanced healthcare infrastructures improve the accessibility and effectiveness of GI stool testing by providing advanced laboratory facilities, diagnostic technologies, and better-trained medical professionals. This leads to faster and more accurate detection of gastrointestinal disorders, enabling timely treatment and better patient outcomes. For instance, in November 2024, The Health Foundation, a UK-based independent charity, reported that the Department of Health and Social Care's spending is expected to increase from $227.6 billion in 2023/24 to $238.6 billion in 2024/25, and $250.6 billion in 2025/26, reflecting an average annual real-term growth of 3.3%. As such, the expansion of healthcare infrastructure supports the growth of the GI stool testing market.
Leading companies in the GI stool testing market are prioritizing advanced diagnostic technologies, such as comprehensive tests, to improve accuracy, speed, and early detection of diseases. Comprehensive diagnostic tests evaluate multiple health parameters at once, offering a thorough assessment of a condition. For example, in November 2024, EmeritusDX, a US-based diagnostics company, launched GI Detect, a comprehensive diagnostic test designed to assist healthcare providers in diagnosing gastrointestinal disorders. This innovative test uses a single stool swab to detect 26 bacteria, viruses, and parasites associated with digestive system disturbances. With a 24-hour turnaround time, GI Detect allows for fast and informed clinical decision-making. In addition to broad pathogen detection, the test screens for Helicobacter pylori and its virulence factors-VacA, cagA, and babA-along with common gastrointestinal parasites such as Cryptosporidium, Entamoeba histolytica, and Giardia lamblia. This comprehensive approach ensures accurate and timely diagnosis of gastrointestinal infections.
Major players in the GI stool testing market are Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Hologic Inc., Biomerieux SA, Bio-Rad Laboratories Inc., Meridian BioScience Inc., Diasorin SPA, Helena Laboratories Corporation, ELITechGroup, Genova Diagnostics Inc., Genesis Laboratory Management LLC, US BioTek Laboratories LLC, Doctor's Data Inc., Diagnostic Solutions Laboratory LLC, Serosep Ltd., Atlas Laboratories Ltd., VDI Laboratory LLC, Functional Medical Institute Pvt. Ltd., Walk-In Lab LLC, and ScheBo Biotech AG.
North America was the largest region in the GI stool testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in GI stool testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the GI stool testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The GI stool testing market consists of revenues earned by entities by providing services such as microbiome analysis, pathogen detection, colorectal cancer screening, digestive health assessment, and inflammatory marker testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The GI stool testing market also includes sales of stool test kits, reagent solutions, sample collection devices, diagnostic analyzers, and laboratory consumables. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
GI Stool Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on gi stool testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for gi stool testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gi stool testing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.